In brief: Cytopia; LCT; Rockeby
Thursday, 10 March, 2005
Cytopia (ASX:CYT) today filed an Investigational New Drug Application with the US Food and Drug Administration, seeking approval to test its cancer drug candidate CYT997 in the clinic.
Rockeby biomed (ASX:RBY) has announced the resignation of Dr John Warmington as the company's director of research and development. Warmington assume a consultancy role with the company as chief scientist. Dr David Capes will take up the position of vice president of research and development.
Xenotransplantation company Living Cell Technologies (ASX: LCT) has appointed Paris Brooke as general manager. Brooke was formerly policy and communication manager at AusBiotech.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
